Since the origin of the wild strain of SARS-CoV-2, several variants have emerged, which
were designated as VOC, VOI, and VUM from time to time. The Omicron variant is noted as …

Coronavirus disease 2019 (COVID-19), the pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), which counts more than 650 million cases and …

Recombination is the main contributor to RNA virus evolution, and SARS‐CoV‐2 during the
pandemic produced several recombinants. The most recent SARS‐CoV‐2 recombinant is …

Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Mucosal immunity plays a significant role in the first-line defense against viruses transmitted
and infected through the respiratory system, such as SARS-CoV-2. However, the lack of …

Previous studies on the Omicron BA. 2 variant suggested that the virological characteristics
of BA. 2 are determined by the mutations in at least two different regions of the viral genome …

The severe acute respiratory syndrome coronavirus 2 EG. 5 lineage is the latest variant
under monitoring, and it is generating significant concern due to its recent upward trend in …

The novel coronavirus, SARS-CoV-2, part of the Coronaviridae family, was discovered in
December 2019 in China. World Health Organization named it COVID-19 and by March …

The recent emergence of different SARS-CoV-2 variants creates an urgent need to develop
more effective therapeutic agents to prevent COVID-19 outbreaks. Among SARS-CoV-2 …

Recombination events are very common and represent one of the primary drivers of RNA
virus evolution. The XBF SARS-CoV-2 lineage is one of the most recently generated …